最近最经典中文mv字幕-最近韩国电影免费高清hd-最近的中文字幕大全免费-最近日韩中文字幕中文翻译歌词

您好,歡迎來到上海士研管理咨詢有限公司
產業峰會 演講局 專家智庫服務 峰會活動服務 整合營銷服務
  • 產業峰會:
    以專業團隊對產業和市場客觀詳實地調研為前提,擁有戰略性、系統性、全球性的基因,匯集了領導者關注的熱點話題與領袖代表,為您提供“一站式”的對話、分享、社交平臺!
  • 演講局:
    致力于為全球企業和機構提供主題演講家、高管大師班、董事會顧問,每項服務都提供了一種更深入、更具互動性的體驗,尤其是針對較小的精選受眾和關鍵個人。我們擁有最具影響力的商業領袖和頂級專家的資源,他們是各自領域的最杰出的代表。我們的團隊由經驗豐富的演講和活動經理組成,我們注重建立長期而深入的伙伴關系。
  • 專家智庫服務:
    中國領先的行業專家知識信息服務供應商,為需要專業洞見的商業決策者匹配具有一手經驗的行業專家,助力他們以更加明確的目標和堅定的信心做出決策。我們有60萬余名專家顧問遍布二十多個行業,而且每天還在增加!
  • 峰會活動服務:
    致力于成為全球最專業的產業峰會活動提供商,為企業和機構的產業性峰會活動提供一站式專業服務,包括調研策劃、定制邀請、營銷推廣、運營組織、項目管理、直播與數字化會議等,每項服務都由經驗豐富的專業團隊匹配長期沉淀的產業資源予以卓越執行,我們注重建立長期而深入的伙伴關系。
  • 整合營銷服務:
    致力于成為全球領先的2B營銷服務機構,聚焦產業高端活動、內容、渠道的建設與沉淀,為客戶提供一站式整合營銷解決方案,助力企業線上線下獲客與品牌筑造。我們深信專業團隊匹配產業資源帶來卓越執行,我們注重建立長期而深入的伙伴關系。
嘉賓信息
發布時間: 2018 - 11 - 09
點擊次數: 0
所屬職位: 董事長
所屬公司: 方恩(天津)醫藥發展有限公司
個人簡介:
Dr. Dan Zhang is the Executive Chairman of Fountain Medical Development Ltd, a clinical CRO with 1700 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia & USA.Dr. Zhang was the Head of Clinical Development and was the Head of Safety Assessment at Sigma-Tau Research Inc-leading Italian Pharmaceutical Company, He was the vice president at the Quintiles Transnational Corp., the world largest clinical CRO,  and Chairman of Quintiles Medical Development (Shanghai) Company Ltd.Dr. Zhang is a member of grant review committee for National Drug Development Fund of China, and is also a consultant for the China Food and Drug Administration (CFDA). He is a member of ICH E19 Expert Working Group. He is also chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. Dr. Zhang is also a senior consultant for the Chinese Academy of Medical Sciences and Peking Union Medical College. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China, and was the secretary-general of the Association of “Thousand Talent” Expert from 2011-2017. Dr. Zhang was the former board of directors for the Sino-American Pharmaceutical Association (SAPA) and was the former president of Chinese Biopharmaceutical Association-USA (CBA). Dr. Zhang is chairing the government relationship committee of Bayhelix-an organization hosting senior executives from life-science organizations in USA and China.Dr. Zhang received his pre-med training from Peking University and received M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998.
發布時間: 2018 - 11 - 14
點擊次數: 0
所屬職位: 運營合伙人
所屬公司: 鼎豐生科資本
個人簡介:
Ben joined Pivotal Bioventure Partners as an Operating Partner from April, 2017. Ben has overall 24+ years’ extensive experience of global pharmaceutical R&D and business development in addition to building small biotech and CRO.  Before joining us, Dr. Ben Ni was CEO of iPharma (H.K) Ltd  (and i-Bridge operating partner) and from 2010-2017, Ben was the Head of External Innovation & Partnering, Strategy and Business Development, responsible for Sanofi licensing, transaction & partnering, from Asia pacific region. Since 1994, Ben worked as member of senior management team  in several global healthcare/pharmaceutical companies such as Eli Lilly/US (Action Group Chair), Covance (General Manager, Greater China), GSK (Neurodegenerative Disease Center, Global head ) where Ben has the proven track record of transitioning compounds from drug discovery/research phase into clinical development in several therapeutic areas and  plays pivotal roles in global R&D, Clinical service management in China. His value-add lies in broad and diverse scientific and business management expertise/knowledge in multi sectors of global healthcare industry under multi-culture environment in US and Asia.Ben has 40 publications in top international journals including Science, PNAS, five book chapters and four granted US patents. Ben is also adjunct professor in several universities in US and Singapore. Ben has been invited speaker in 60 international conferences and professional seminars.Ben holds a Ph. D in molecular pharmacology from University of Toronto under fellowship and post-doctoral fellowship in Clinical Pharmacology from National Institute of Health.
發布時間: 2018 - 11 - 14
點擊次數: 0
所屬職位: 創始人兼CEO
所屬公司: 上海岸邁生物科技有限公司
個人簡介:
吳辰冰博士從美國佐治亞大學生物化學系獲得生物化學與分子生物學博士后,進入美國哈佛醫學院進行博士后研究,獲得美國癌癥研究中心的研究基金,主要從事分子免疫學的研究,在揭示XLP疾病的機理方面有重要突破。后來進入雅培制藥公司生物研究中心,從事治療性抗體的研究與開發十多年,帶領多個項目從早期研究開始成功進入到臨床申報。吳博士長期從事分子免疫及抗體藥物研究工作,有多篇首席作者論文發表在Nature Immunology和Nature Biotechnology等國際一流學術刊物,并有多項國際專利授權和50多項國際專利申請。 之后吳博士回國加入上海睿智化學研究有限公司,建立了一個全方位的治療性抗體研發平臺,并借此與國內外生物醫藥企業廣泛合作,成功地開發出一些有影響力的創新抗體藥物。吳博士于2013年加盟上海中信國健藥業股份有限公司,擔任首席科學官兼研究院院長,主要致力于完善研發梯隊,建立技術平臺,充實研發管線,制定研發策略,并入選浦東百人。2016年5月吳博士開始擔任上海岸邁生物科技有限公司總裁,主要進行新一代生物大分子的技術開發及產品研發,帶領團隊開發出新一代的雙特異性抗體平臺技術“FIT-Ig”,目前已有多種由該技術開發出來的新型抗體進入臨床申報階段,未來將致力于建立一個創新型國際化的生物制藥企業。 2017年初岸邁生物成功完成2500萬美元A輪融資,其首個抗腫瘤產品獲十三五重大專項立項,并榮獲中國創新創業大賽生物組(初創企業)行業全國總決賽冠軍。
發布時間: 2018 - 11 - 14
點擊次數: 0
所屬職位: 首席執行官、創始人,首席科學官
所屬公司: 華領醫藥
個人簡介:
陳力博士,華領醫藥有限公司董事、首席執行官、創始人,首席科學官。陳力博士曾任羅氏研發中國有限公司首席科學官,擁有20多年新藥研發創新及管理經驗。陳力博士于2011年成立華領醫藥,以“患者為先、創新為本、良藥為民”為宗旨,運用“中西合璧、聯合創新”的新藥研發運營模式和“高標準、高質量、創造高價值”的經營理念,在5年內華領醫藥的糖尿病全球原創新藥HMS5552成功取得中美臨床試驗批件、完成四個臨床I期和臨床II期POC試驗,并在2017年全球率先啟動同類產品III期臨床試驗和藥品上市計劃,實現全球首創、中國首發。在此期間,成功完成2億美元融資和中國新藥創新公司建設。陳力博士1992年畢業于愛荷華州立大學,獲博士學位,同年加入羅氏美國研發中心。在羅氏陳博士從一名藥物化學資深研究員成長為高通量技術部主任,2004年回中國建立羅氏中國研發中心,任首席科學官和董事。陳力博士是35件授權專利發明人和17件專利申請發明人, 并發表60多篇科學論文。
微信公眾號
領導者網絡APP
友情鏈接
Copyright ?2005 - 2017上海士研管理咨詢有限公司
犀牛云提供企業云服務